Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Femasys Inc. on March 20, 2026, covering events occurring on March 17, 2026, and March 19, 2026. The filing details amendments to a prior financing agreement and changes to the Board of Directors.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or liquidity metrics. The primary financial activity reported is the issuance of unregistered equity securities as consideration for debt amendments:
- Instrument Issued: 16,378,563 Series D-1 Warrants.
- Exercise Price: $0.58 per share.
- Underlying Shares: Equal to the number of shares underlying each holder's existing Series A-1 Warrant.
- Exemption: Issued under Section 4(a)(2) of the Securities Act to accredited investors.
Material Changes and Agreements
The Company entered into an Omnibus Amendment and Consent Agreement with requisite holders of its Senior Secured Convertible Notes and Warrants (originally issued November 3, 2025). The material change is the removal of the "Share Combination Event Adjustment" from the Notes and Warrants, effective as of December 31, 2025. In exchange for this amendment, lenders received the Series D-1 Warrants described above.
Management Commentary, Governance, and Risks
Board Changes:
- Resignation: Joshua Silverman resigned as a director effective March 17, 2026. The Company stated the resignation was not due to any dispute regarding operations, policies, or practices.
- Appointment: Kenneth D. Eichenbaum, M.D., M.S.E., was appointed as a director effective March 18, 2026.
- Nomination Rights: Dr. Eichenbaum was appointed pursuant to a board nomination right granted to Pointillist Global Macro Series (the "Lead Lender") under the November 2025 Securities Purchase Agreement. This right falls away if the Lead Lender's beneficial ownership drops below 4.99% (on an as-converted basis), upon full payment of the Notes, or on November 7, 2030.
- Independence: The Board determined Dr. Eichenbaum is an independent director and he will serve on the Nominating and Corporate Governance Committee.
Risks and Contingencies: The Series D-1 Warrants and underlying shares are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Review the full text of the Omnibus Amendment and Consent Agreement (Exhibit 10.1) to understand the specific terms of the removed Share Combination Event Adjustment.
- Examine the form of the Series D-1 Warrant (Exhibit 4.1) for exercise conditions, expiration dates, and anti-dilution provisions.
- Verify the current beneficial ownership percentage of Pointillist Global Macro Series to assess the duration of their board nomination rights.
- Confirm the total number of outstanding shares and the potential dilution impact of the 16,378,563 new warrants.